Nexalin Technology (NXL) Asset Writedowns and Impairment (2022 - 2024)
Nexalin Technology's (NXL) quarterly Asset Writedowns and Impairment came in at $496.0 in Q1 2024, down 63.82% year-on-year from $1371.0 in Q2 2023, and down 68.08% quarter-over-quarter from $1554.0 in Q4 2023.
Nexalin Technology (NXL) Asset Writedowns and Impairment (2022 - 2024) Analysis & Trends
Nexalin Technology's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $496.0 for Q1 2024.
- On a quarterly basis, Asset Writedowns and Impairment fell 63.82% year-over-year to $496.0 in Q1 2024; TTM through Dec 2024 was $496.0, a 91.39% decrease from a year earlier, with the FY2025 full-year figure at $16380.0, up 3202.42% from the prior year.
- Asset Writedowns and Impairment eased to $496.0 in Q1 2024 per NXL's latest filing, from $1554.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $8639.0 in Q3 2022 and bottomed at -$5987.0 in Q4 2022.
- The 3-year median for Asset Writedowns and Impairment is $1371.0 (2023), against an average of $1271.8.
- Biggest YoY gain for Asset Writedowns and Impairment was 125.96% in 2023; the steepest drop was 83.4% in 2023.
- Year by year, Asset Writedowns and Impairment stood at -$5987.0 in 2022, then soared by 125.96% to $1554.0 in 2023, then sank by 68.08% to $496.0 in 2024.
- Per Business Quant, the three latest NXL Asset Writedowns and Impairment figures stand at $496.0 (Q1 2024), $1554.0 (Q4 2023), and $1434.0 (Q3 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 496.00 |
| Mar 31, 2024 | 496.00 |
| Dec 31, 2023 | 1,554.00 |
| Dec 31, 2023 | 1,554.00 |
| Sep 30, 2023 | 1,434.00 |
| Sep 30, 2023 | 1,434.00 |
| Jun 30, 2023 | 1,403.00 |
| Jun 30, 2023 | 1,403.00 |
| Mar 31, 2023 | 1,371.00 |
| Mar 31, 2023 | 1,371.00 |
| Dec 31, 2022 | -5,987.00 |
| Dec 31, 2022 | -5,987.00 |
| Sep 30, 2022 | 8,639.00 |
| Sep 30, 2022 | 8,639.00 |
| Jun 30, 2022 | 1,282.00 |
| Jun 30, 2022 | 1,282.00 |
| Mar 31, 2022 | 1,254.00 |
| Mar 31, 2022 | 1,254.00 |